- Home
- MRK vs NVS Comparison
MRK vs NVS Comparison
Compare MRK & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRK
- NVS
- Stock Information
- Founded
- MRK 2000
- NVS 1895
- Country
- MRK United States
- NVS Switzerland
- Employees
- MRK N/A
- NVS N/A
- Industry
- MRK Biotechnology: Pharmaceutical Preparations
- NVS Biotechnology: Pharmaceutical Preparations
- Sector
- MRK Health Care
- NVS Health Care
- Exchange
- MRK Nasdaq
- NVS Nasdaq
- Market Cap
- MRK 218.2B
- NVS 230.5B
- IPO Year
- MRK N/A
- NVS 1991
- Fundamental
- Price
- MRK $76.82
- NVS $115.75
- Analyst Decision
- MRK Buy
- NVS Hold
- Analyst Count
- MRK 15
- NVS 6
- Target Price
- MRK $113.71
- NVS $123.67
- AVG Volume (30 Days)
- MRK 14.7M
- NVS 1.7M
- Earning Date
- MRK 04-24-2025
- NVS 07-17-2025
- Dividend Yield
- MRK 4.22%
- NVS 3.45%
- EPS Growth
- MRK 667.14
- NVS N/A
- EPS
- MRK 6.88
- NVS 6.38
- Revenue
- MRK $63,922,000,000.00
- NVS $53,222,000,000.00
- Revenue This Year
- MRK $2.42
- NVS $7.22
- Revenue Next Year
- MRK $5.64
- NVS $1.94
- P/E Ratio
- MRK $11.17
- NVS $17.41
- Revenue Growth
- MRK 4.10
- NVS 11.50
- 52 Week Low
- MRK $73.31
- NVS $96.06
- 52 Week High
- MRK $134.63
- NVS $120.92
- Technical
- Relative Strength Index (RSI)
- MRK 44.17
- NVS 62.89
- Support Level
- MRK $75.59
- NVS $111.06
- Resistance Level
- MRK $78.20
- NVS $113.91
- Average True Range (ATR)
- MRK 2.03
- NVS 1.57
- MACD
- MRK 0.21
- NVS 0.45
- Stochastic Oscillator
- MRK 44.10
- NVS 98.99
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.